Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma

References

• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive NHL. N Eng J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1131–1137
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol-a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025–3030
   PubMed Web of Science ®Google Scholar
• Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschluter M, et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica 2003; 88: 1304–1315
   PubMed Web of Science ®Google Scholar
• Kaiser U, Uebelacker I, Abel U, Birkmann J, Truemper J, Schmalenberg H, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for ‘aggressive’ lymphoma. J Clin Oncol 2002; 20: 4413–4419
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472–2479
   PubMed Web of Science ®Google Scholar
• Martelli M, Gherlinzoni F, De Renzo A, Zinzani P L, De Vivo A, Cantonetti M, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol 2003; 21: 1255–1262
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S, Williams M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Vose J M, Link B K, Grossbard M L, Czuczman M S, Grillo-Lopez A, Gilman P, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389–397
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Litchy S, Burris H A, III, Scullin D C, Corso S W, Yardley D A, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261–4267
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Grillo-Lopez A J, White C A, Saleh M, Gordon L, LoBuglio A F, et al. Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–276
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Fallon A, Scarpace A, Steweart C, Bernstein Z P, Mccarthy P, et al. Phase II study of rituximab in combination with fludarabine in patients with low-grade or follicular B‐cell lymphoma. Blood 2000; 96(Suppl 1)729, (abstr)
   Google Scholar
• Czuczman M S, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez A J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711–4716
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Briere J, Herbrecht R, Tilly H, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell non-Hodgkin's lymphoma. N Eng J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Carbone P P, Kaplan H S, Musshof K. Report of the committee in Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Intragumtornchai T, Prayoonwiwat W, Numbenjapon T, Assawametha N, O'Charoen R, Swasdikul D. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate and high-risk non-Hodgkin's lymphoma. Clinical Lymphoma 2000; 1: 219–225
   PubMedGoogle Scholar
• Cox D R. Regression models and life tables. Journal of the Royal Statistics Society 1972; 34: 187–220
   Google Scholar
• Pfreundschuh M G, Truemper L, Ma D, Östenborg A, Pettengell R, Trneny M, et al. Randomized intergroup trial of first line treatment for patients ≤60 years with diffuse large B-cell non-Hodgkin's lymphoma with a CHOP-like regimen with or without anti-CD20 antibody rituximab-early stopping after the first interlim analysis. Proceedings of the American Society of Clinical Oncology 2004; 23: 556, (abstr)
   Google Scholar
• Coiffier B, Herbretch R, Morel P, Tilly H, Sebban C, Feugier P, et al. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with an analysis according to co-morbid factors. Hematology Journal 2003; 4(Suppl2)111, (abstr)
   Google Scholar
• Philip T, Guglielmi C, Hagebeek A, Somers R, van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage therapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Eng J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Eng J Med 2004; 350: 1287–1295
   PubMed Web of Science ®Google Scholar
• Hahn T, Wolff S N, Czuczman M, Fisher R I, Lazarus H M, Vose J, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review. Biology & Blood Marrow Transplantation 2001; 7: 308–331
   PubMed Web of Science ®Google Scholar
• Velasquez W S, McLaughlin P, Tucker S, Hagemeister F B, Swan F, Rodriguez M A, et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow up study. J Clin Oncol 1994; 12: 1169–1176
   PubMed Web of Science ®Google Scholar
• Bieker R, Kessler T, Berdel W E, Mesters R M. Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma. Oncol Rep 2003; 10: 1915–1917
   PubMed Web of Science ®Google Scholar
• Cocconi G, Franciosi V, Dodero A, Bologna A, Vasini G, De Lisi V, et al. P-CHOP: Cisplatin (P) added to the standard CHOP as first-line treatment for aggressive non-Hodgkin lymphoma. A single-institution phase II study. Am J Clin Oncol 2003; 26: 535–542
   PubMed Web of Science ®Google Scholar
• Armitage J O, Vose J M, Linder J, Weisenburger D, Harrington D, Casey J, et al. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma. J Clin Oncol 1989; 7: 1783–1790
   PubMed Web of Science ®Google Scholar
• Coiffier B, Berger F, Bryon P A, Magaud J P. T-cell lymphomas: immunologic, histologic, clinical and therapeutic analysis of 63 cases. J Clin Oncol 1988; 6: 1584–1589
   PubMed Web of Science ®Google Scholar
• Lippman S M, Miller T P, Spier C M, Slymen D J, Grogan T M. The prognostic significance of the immunophenotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype. Blood 1988; 72: 436–441
   PubMed Web of Science ®Google Scholar
• Intragumtornchai T, Rotnakkarin T, Sutcharitchan P, Wannakrairot P. Prognostic significance of the immunophenotype versus the international prognostic index in aggressive non-Hodgkin's lymphoma. Clinical Lymphoma 2003; 4: 52–55
   PubMedGoogle Scholar
• Feugier P, Virion J M, Tilly H, Haioun C, Macro M, Bordessoule D, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large B-cell lymphoma: influence of rituximab. Ann Oncol 2004; 15: 129–133
   PubMed Web of Science ®Google Scholar